Life-threatening hemophagocytic syndrome triggered by disseminated toxoplasmosis in a young patient with previously unknown AIDS
Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved..
Hemophagocytic syndrome is a rare life-threatening disorder that can be triggered by various conditions such as HIV infection and opportunistic agents. We report a case of disseminated toxoplasmosis complicated with severe hemophagocytic syndrome and revealing an unknown acquired immunodeficiency syndrome. The patient presented with multiple organ failure in intensive care unit. Once diagnosed, he benefitted from etoposide infusion, administration of specific anti-toxoplasmosis treatments and secondary antiretroviral therapy. He was alive at intensive care unit discharge and returned home with little sequalae. This case illustrates both the importance of rapid investigations of hemophagocytic syndrome etiologies in HIV positive patients and the necessity to prompt etoposide and specific treatments in order to improve potentially dramatic outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
La Revue de medecine interne - 43(2022), 10 vom: 09. Okt., Seite 622-625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guiraud, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 06.10.2022 Date Revised 06.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.revmed.2022.07.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346064066 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346064066 | ||
| 003 | DE-627 | ||
| 005 | 20231226030533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.revmed.2022.07.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346064066 | ||
| 035 | |a (NLM)36089427 | ||
| 035 | |a (PII)S0248-8663(22)00603-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guiraud, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Life-threatening hemophagocytic syndrome triggered by disseminated toxoplasmosis in a young patient with previously unknown AIDS |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.10.2022 | ||
| 500 | |a Date Revised 06.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Hemophagocytic syndrome is a rare life-threatening disorder that can be triggered by various conditions such as HIV infection and opportunistic agents. We report a case of disseminated toxoplasmosis complicated with severe hemophagocytic syndrome and revealing an unknown acquired immunodeficiency syndrome. The patient presented with multiple organ failure in intensive care unit. Once diagnosed, he benefitted from etoposide infusion, administration of specific anti-toxoplasmosis treatments and secondary antiretroviral therapy. He was alive at intensive care unit discharge and returned home with little sequalae. This case illustrates both the importance of rapid investigations of hemophagocytic syndrome etiologies in HIV positive patients and the necessity to prompt etoposide and specific treatments in order to improve potentially dramatic outcomes | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acquired Immunodeficiency Syndrome | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Immunocompromised Host | |
| 650 | 4 | |a Lymphohistiocytosis, Hemophagocytic | |
| 650 | 4 | |a Toxoplasmosis | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 700 | 1 | |a Verney, C |e verfasserin |4 aut | |
| 700 | 1 | |a Tetelboum, N |e verfasserin |4 aut | |
| 700 | 1 | |a Argy, N |e verfasserin |4 aut | |
| 700 | 1 | |a Debus, J |e verfasserin |4 aut | |
| 700 | 1 | |a Herbel, S |e verfasserin |4 aut | |
| 700 | 1 | |a Thy, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ricard, J D |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, D |e verfasserin |4 aut | |
| 700 | 1 | |a Zucman, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue de medecine interne |d 1983 |g 43(2022), 10 vom: 09. Okt., Seite 622-625 |w (DE-627)NLM012660108 |x 1768-3122 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:10 |g day:09 |g month:10 |g pages:622-625 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.revmed.2022.07.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 10 |b 09 |c 10 |h 622-625 | ||